Finnegan client Astellas Pharma US LLC filed an infringement suit June 21 in the District of New Jersey against Sagent Pharmaceuticals Inc. and Strides Arcolab Ltd., related to their recent ANDA application seeking approval to make a generic version of Adenoscan®, used as an adjunct to thallium-201 myocardial perfusion scintigraphy in the diagnosis of coronary artery disease patients who are not able to exercise adequately. Astellas is represented by Finnegan in this matter.